Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.46 |
| ▸ | BDKRB2 | P30411 | 2/20 | 0.41 |
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30414346 | 0.96 | GRB2 (0.42) | OPRM1OPRD1BDKRB2GRB2CAPN1 | |
| SCHEMBL29468766 | 0.92 | GRB2 (0.42) | OPRM1OPRD1BDKRB2GRB2CAPN1 | |
| SCHEMBL30543480 | 0.90 | GRB2 (0.46) | OPRM1OPRD1BDKRB2GRB2 | |
| SCHEMBL30626180 | 0.88 | OPRM1 (0.51) | OPRM1OPRD1BDKRB2GRB2CAPN1 | |
| SCHEMBL29397180 | 0.88 | OPRM1 (0.51) | OPRM1OPRD1BDKRB2GRB2CAPN1 | |
| SCHEMBL29468832 | 0.88 | GRB2 (0.46) | OPRM1OPRD1BDKRB2GRB2 | |
| SCHEMBL30543475 | 0.87 | GRB2 (0.41) | OPRM1OPRD1BDKRB2GRB2CAPN1 | |
| SCHEMBL31337813 | 0.87 | GRB2 (0.44) | OPRM1OPRD1BDKRB2GRB2CMA1 | |
| SCHEMBL29468889 | 0.87 | GRB2 (0.42) | OPRM1OPRD1BDKRB2GRB2CAPN1 | |
| SCHEMBL30184771 | 0.86 | OPRM1 (0.47) | OPRM1OPRD1BDKRB2GRB2CAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | SHENZHEN TURIER BIOTECH CO., LTD. (CN) | 2023-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364194-A1 | GLP-1R/GCGR Dual Target Agonist Polypeptide Derivative for Treatment of Hepatic Fibrosis Associated with Viral Hepatitis | GLP1R, GCGR, GIPR | OPRM1 3338/4885OPRD1 2819/4885BDKRB2 288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.